Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Comment: Immunogenicity of biosimilars

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 08.10.19
Views: 466
Rating:

Prof Arnold Vulto - Erasmus University Rotterdam, Rotterdam, Netherlands

Prof Arnold Vulto speaks to ecancer at the 2019 Biosimilars Educational Advanced Masterclass for Pharmacists (P-BEAM) in Zurich about the effect of infliximab, rituximab and adalimumab on immunogenicity.

He mentions that these reference products have high antibody titres and are highly similar to their respective biosimilar.

Prof Vulto emphasises that the immunogenicity of these biosimilars is no different from the reference product.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

If you would like to learn more about biosimilar medicines, please visit our free e-learning modules here.

 

Related videos

follow us

Immuno-oncology advances in cancer treatment e-learning


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation